High-resolution functional mapping of RAD51C by saturation genome editing.

RAD51C cancer predisposition homologous recombination saturation genome editing

Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
16 Sep 2024
Historique:
received: 21 07 2023
revised: 29 02 2024
accepted: 20 08 2024
medline: 20 9 2024
pubmed: 20 9 2024
entrez: 19 9 2024
Statut: aheadofprint

Résumé

Pathogenic variants in RAD51C confer an elevated risk of breast and ovarian cancer, while individuals homozygous for specific RAD51C alleles may develop Fanconi anemia. Using saturation genome editing (SGE), we functionally assess 9,188 unique variants, including >99.5% of all possible coding sequence single-nucleotide alterations. By computing changes in variant abundance and Gaussian mixture modeling (GMM), we functionally classify 3,094 variants to be disruptive and use clinical truth sets to reveal an accuracy/concordance of variant classification >99.9%. Cell fitness was the primary assay readout allowing us to observe a phenomenon where specific missense variants exhibit distinct depletion kinetics potentially suggesting that they represent hypomorphic alleles. We further explored our exhaustive functional map, revealing critical residues on the RAD51C structure and resolving variants found in cancer-segregating kindred. Furthermore, through interrogation of UK Biobank and a large multi-center ovarian cancer cohort, we find significant associations between SGE-depleted variants and cancer diagnoses.

Identifiants

pubmed: 39299233
pii: S0092-8674(24)00968-1
doi: 10.1016/j.cell.2024.08.039
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Rebeca Olvera-León (R)

Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Querétaro, Mexico.

Fang Zhang (F)

Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA; Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Victoria Offord (V)

Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.

Yajie Zhao (Y)

MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.

Hong Kee Tan (HK)

Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.

Prashant Gupta (P)

Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.

Tuya Pal (T)

Department of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center (VUMC)/Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN, USA.

Carla Daniela Robles-Espinoza (CD)

Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Querétaro, Mexico.

Fernanda G Arriaga-González (FG)

Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Querétaro, Mexico.

Larissa Satiko Alcantara Sekimoto Matsuyama (LSAS)

Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.

Erwan Delage (E)

Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.

Ed Dicks (E)

Department of Public Health and Primary Care, University of Cambridge, Robinson Way, Cambridge, UK.

Suzana Ezquina (S)

Department of Public Health and Primary Care, University of Cambridge, Robinson Way, Cambridge, UK.

Charlie F Rowlands (CF)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

Clare Turnbull (C)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; National Cancer Registration and Analysis Service, National Health Service (NHS) England, London, UK; Cancer Genetics Unit, The Royal Marsden NHS Foundation Trust, London, UK.

Paul Pharoah (P)

Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

John R B Perry (JRB)

MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.

Maria Jasin (M)

Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Andrew J Waters (AJ)

Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. Electronic address: aw28@sanger.ac.uk.

David J Adams (DJ)

Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. Electronic address: da1@sanger.ac.uk.

Classifications MeSH